These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 22147859

  • 21. Patterns of prescribing antiepileptic drugs for bipolar disorder.
    Kish-Doto J, Evans WD, Squire C, Williams P, Ranney LM, Melvin CL.
    J Psychiatr Pract; 2008 Mar; 14 Suppl 1():35-43. PubMed ID: 19034208
    [Abstract] [Full Text] [Related]

  • 22. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
    Roehr B.
    BMJ; 2012 Dec 06; 345():e8324. PubMed ID: 23220261
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going?
    Joseph JN, Deaton D, Ehsan H, Bonanno MA.
    J Health Life Sci Law; 2009 Jan 06; 2(2):73-108. PubMed ID: 19288889
    [Abstract] [Full Text] [Related]

  • 25. United States v. Caronia: The increasing strength of commercial free speech and potential new emphasis on classifying off-label promotion as "false and misleading".
    Scheineson MJ, Cuevas G.
    Food Drug Law J; 2013 Jan 06; 68(2):201-16, iii. PubMed ID: 24640469
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Doctor explains why he blew the whistle.
    Petersen M.
    N Y Times Web; 2003 Mar 12; ():C1, C2. PubMed ID: 12812161
    [No Abstract] [Full Text] [Related]

  • 29. Dicing with death : there's a good chance that the pills your doctor prescribed will do you no good and might even harm you.
    Muir H.
    New Sci; 2003 Mar 12; 191(2562):38-41. PubMed ID: 17115486
    [No Abstract] [Full Text] [Related]

  • 30. Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.
    Bagley CE, Mitts J, Tinsley RJ.
    Cornell J Law Public Policy; 2013 Mar 12; 23(2):337-93. PubMed ID: 25330567
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases.
    Liu S, Mello MM, Kesselheim AS.
    J Health Polit Policy Law; 2021 Jun 01; 46(3):487-504. PubMed ID: 33647951
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. FDA approved new drug bulletin. Gabapentin (neurontin).
    RN; 1994 Jul 01; 57(7):39-40. PubMed ID: 8047795
    [No Abstract] [Full Text] [Related]

  • 35. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K.
    N Engl J Med; 2014 Jul 03; 371(1):1-3. PubMed ID: 24988551
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Company pays over $81m for allegedly promoting topiramate for unapproved uses.
    Kmietowicz Z.
    BMJ; 2010 May 27; 340():c2848. PubMed ID: 20508021
    [No Abstract] [Full Text] [Related]

  • 40. Apparent discrepancy between published study of gabapentin treatment and internal company report.
    Mayo-Wilson E.
    J Clin Psychiatry; 2013 Aug 27; 74(8):853-4. PubMed ID: 24021509
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.